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Abstract
Background: To determine the effect of higher progesterone (P) level on endometrial receptivity.
Methods: This was a prospective analysis conducted in the Reproductive Medical Center of Peking University Third
Hospital. All patients received IVF treatment and canceled embryo transfer in the same cycle and were divided into
group 1 (normal P; 7 patients) and group 2 (elevated P; 12 patients). Endometrial biopsies were performed 6 days
after oocyte retrieval. The global miRNA and mRNA gene expressions in endometrial biopsies were investigated
with a V4.0 miRNA probe and 22 K Human Genome Array. Fold ratios were derived to compare gene regulation
between the groups. Spp1 and Ang gene expression was selected to verify the array results by RT-PCR and the
protein expression of osteopontin and VEGF was determined using an immunohistochemical method.
Results: There were 4 miRNA (all down-regulated) and 22 mRNA (13 up-regulated and 9 down-regulated)
exhibiting differential expression between the groups on the microRNA and microarray chips. miRNA-451, Spp1, and
Ang expression in RT-PCR verified the array results. Osteopontin and VEGF were also shown to have positive
expression in the endometrium.
Conclusions: Data from microRNA and microarray analysis suggests dissimilar endometrial receptivity in patients
with high P levels on the day of hCG, and elevated osteopontin and decreased VEGF had poor pregnancy rates.
Background
Elevated serum progesterone (P) on the day of human
chorionic gonadotrophin (hCG) has been reported to
occur in 20%-40% of in vitro fertilization (IVF) and
embryo transfer (ET) cycles [1]. Our clinical research has
shown the pregnancy outcome was much poorer (13.79
versus 44.68%) if the serum P on the day of hCG was >6.0
nmol/l. However, the potential effect of these subtle
increases on implantation remains controversial. Some
argue that high serum P concentrations could have an
adverse effect on oocyte quality or endometrial conditions
[2]. Recent clinical studies have supported this notion
of decreased endometrial receptivity. Melo et al. [3]
conducted experiments involving patients in oocyte dona-
tion cycles (two cycles per woman, one normal and
another P elevation cycle). The recipient’s pregnancy rates
were similar per IVF-ET, whether or not P was elevated.
Our clinical research also showed that patients with ele-
vated P had a poor outcome of fresh ET cycles, but a simi-
lar successful outcome in frozen embryo transfer (FET)
cycles compared with the normal P group [4]. These
reports further confirmed the link between poor preg-
nancy rates and decreased endometrial receptivity in
patients with elevated P, not fertilization or embryo
quality.
Endometrial receptivity is a complex process, both
temporally and spatially restricted. Improved endometrial
receptivity and embryo preparation should lead to
increased pregnancy rates and reduced early pregnancy
failure [5]. It is generally assumed that the receptive
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19-24 [6], and days 8-10 post-ovulation [7]. Endometrial
receptivity has been extensively studied, with a number
of biochemical markers for endometrial receptivity hav-
ing been proposed [8], including integrin and leukaemia
inhibitory factor (LIF), although none of the biomarkers
has proven to be clinically useful as an indicator [9]. In
fact, many factors can play roles in endometrial receptiv-
ity, making it difficult to gain a clear understanding of
gene regulation in the endometrium [10]. Are there any
such uterine markers of endometrial receptivity asso-
ciated with higher P levels?
During the past few years, both complementary DNA
(cDNA) and oligonucleotide microarray technologies
have been successfully applied to the study of endome-
trial gene expression [11]. The availability of this tech-
nology makes it possible to investigate the endometrial
receptivity process from a global genomic perspective
[12]. miRNAs are small (approximately 22 nt) ribonu-
cleotides found in both animal and plant cells which
play important roles in cellular differentiation, tissue
development, and apoptosis by regulating gene expres-
sion and protein translation. Therefore, the current
investigation sought to identify miRNAa- and mRNAs
associated with the development of endometrial recep-
tivity by comparing global gene expression patterns in
normal and elevated P endometrium. Characterization
of the complex relationship between miRNAs and the
target mRNAs in endometrial receptivity may assist in
the determination of the molecular pathways that affect
receptivity; however, that cannot be completely eluci-
dated by mRNA gene expression analysis alone. Both
miRNA array and microarray were employed to detect
the main factor acting upon the poor receptivity of
patients with elevated P.
Methods
Patient details and tissue collection
All participants, 25-36 years of age, underwent transvagi-
nal ultrasound and physical examination; none had posi-
tive findings. The patients all had tubal or male factor
infertility. Endocrinopathies, organic diseases, and other
factors affecting endometrial receptivity, such as polycys-
tic ovary syndrome (PCOS), ovarian tumor, polyps,
fibroids, endometriosis, and hydrosalpinx were excluded.
All patients underwent IVF-ET with gonadotrophin-
releasing hormone agonist (GnRHa) and recombinant
FSH (rFSH). A total of 19 endometrial samples were col-
lected in this study and separated into 2 groups. The
mean ages in normal and elevated P groups were 29.63
and 32.07 years, respectively (P >0 . 0 5 ) .G r o u p1c o n -
sisted of patients with normal P levels (serum P levels
<4.0 nmol/L on the day of hCG) and included 7 patients
who had opted out of ET in order to avoid ovarian
hyperstimulation syndrome (OHSS) in IVF-ET cycles.
G r o u p2c o n s i s t e do fp a t i e nts with elevated P levels
(serum P levels >6.0 nmol/L on the day of hCG, which
was defined by our clinical research [4]), including 12
patients who had cancelled fresh ET in hopes of improv-
ing the chances for success during frozen ET cycles.
Endometrial tissue biopsies were performed by dilation
and curettage 6 days after oocyte retrieval. Each endome-
trial sample was further divided for the following studies:
one portion was used for routine histologic processing
and immunohistochemistry (IHC) in paraffin blocks to
assess Noyes staging; the remainder was immersed in
RNA Later solution and stored at -80°C until RNA
extraction. Ten samples (5 per group) were evaluated for
the expression of miRNAs and mRNAs.
Informed consent was obtained for all patients under-
going endometrial biopsies; these protocols were
approved by the Ethics Committee of Peking University
Third Hospital.
miRNA isolation labeling and microcrarry analysis
Five endometrial samples from patients in each group
were used for microarray hybridization according to the
manufacturer’s instructions. Samples from all patients
were detected independently. Total RNA was extracted
from endometrial samples. Methylaldehyde degeneration
gel electrophoresis was performed to further confirm RNA
integrity. Low molecular weight RNA was isolated using
the PEG solution precipitation method, according to a
previous protocol [13]. The T4 RNA ligase labeling
method was adopted according to the Thomson protocol
[14]. Microarrays were scanned with a confocal Lux-
Scan™scanner (CapitalBio Corp., Beijing, China); scanning
settings were adjusted to obtain a visualized balanced of
U6 and tRNA signals across arrays. Data were extracted
from the TIFF images using LuxScan™3.0 software (Capi-
talBio Corp.). The microarray intensity data were analyzed
by using Significance Analysis of Microarrays (SAM) soft-
ware. Two class unpaired t-tests were performed to iden-
tify miRNA expressed differences among the three groups.
Genes possessing a q-value equal to 0 and a fold-change
>2 were considered significantly different.
Messenger RNA profiling with microarray analysis
Messenger RNA was analyzed from samples in parallel
with the miRNA extraction procedures (see Methods sec-
tion above). A total of 21,522 well-substantiated human
mRNA genes were analyzed using the 22 K Human Gen-
ome Array (CapitalBio Corp.). Two μgo ft o t a lR N Aw a s
reverse-transcribed, and then double-stranded cDNAs
(containing the T7 RNA polymerase promoter sequence)
were synthesized using the CbcScript reverse transcrip-
tase with cDNA synthesis system, according to the man-
ufacturer’s protocol (Capitalbio) with the T7 oligo (dT).
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levels of expression, statistical comparisons were done
using the two classes unpaired t-tests in SAM software in
order to identify the functional classes (gene ontology) of
selected genes.
Real-time PCR
To verify the array results, 3 samples per group were cho-
sen. Real-time PCR reactions were performed using
miRNA and mRNA specific primers for miRNA-451 (miR-
451), the lowest expression of miRNA, Spp1,a n dAng
expression. The GenBank accession numbers of each
gene, along with the primer sequences and PCR product
sizes of the amplified fragment are listed in Table 1. Five
mg of total RNA extracted from each sample was digested
with RNase-free DNase I (Promega, San Luis Obispo, CA
USA) and reverse-transcribed into cDNA using Super-
script II reverse transcriptase (Invitrogen, Carlsbad, CA
USA). mRNA of the housekeeping gene ACTB (forward
primer: AAGTACTCCGTGTGGATCGG; and reverse
primer: ACATCTGCTGGAAGGTGGAC) was used as an
endogenous control. Duplicate samples of the target and
reference genes were amplified in separate wells; controls
without the RT step were included for each primer pair to
check for any contaminants. Melting (dissociation) curves
of PCR reactions were monitored to ensure a single PCR
product and no primer dimmer. All experiments were
repeated 40 cycles. The relative expression ratio of a target
gene was calculated based upon efficiency and the CT
deviation of an unknown sample versus the control (using
myometrium cDNA as a calibrator); this was expressed in
comparison to a reference gene [15]. The mean CT ratios
were expressed as fold differences in gene expression com-
pared with myometrium (gene expression = 1).
Immunohistochemistry methods
After deparaffinizing sections, the section slides were
rehydrated in steps with distilled water (dH2O); slides
were immersed in 0.5% v/v hydrogen peroxide/methanol
for 10 minutes. The antigen retrieval protocol can be car-
ried out at this time, should this procedure be deemed
necessary. Tissue sections were washed in dH2O twice (5
minutes each), then blocked with blocking solution (bio-
tinylated goat anti-rabbit immunoglobulin G). Tissue
sections were quickly labeled with a PAP pen before the
tissue sections dried. After blocking, primary antiserum
diluted in blocking solution (1:100 dilution; Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA) was added
and incubated overnight at 4°C. The sections were incu-
bated with biotinylated secondary antibody diluted in
blocking reagent for 30 minutes at 25°C. Finally, ABCom-
plex/HRP was added for 30 minutes at 25°C; sections
were developed with 3, 3’ diaminobenzidine tetrahy-
drochloride (DAB) and subsequently counterstained with
haematoxylin. The primary antibody was omitted to cre-
ate negative controls.
The immunostaining was scored semi-quantitatively in
each section. The staining intensity and positive percen-
tage were performed independently by two observers
(Li R and Li L), and the mean value was obtained. A
staining score was calculated as follows: H-score=ΣPi
(i+1), where ΣPi is the sum of Pi, Pi = positive cells/100
calculated cells × 100%, and i = intensity score (negative
=0 ,w e a k=1 ,m o d e r a t e=2 ,s t r o n g=3 ) .T h i ss c o r e
value could vary between 0 and 400.
Statistical analysis
Intensity values were analyzed using the SAM method,
which is a statistical technique for finding significant
genes in a set of microarray experiments [16]. Two class
unpaired t-tests were performed to identify mRNA dif-
ferences among the three groups. Genes possessing a
q-value equal to 0 and a fold-change >2 were considered
significantly different. The q-value is the false discovery
rate, which measures how significant the gene is. The
Statistics Package for Social Sciences (SPSS) 13.0 soft-
ware (SPSS Inc., Chicago, IL, USA) was used to analyze
the data by Student’s t-test and rank test. A P <0 . 0 5
was considered statistically significant.
Pathway analysis
In order to identify gene expression, the relationship
between biologic context and pathways was analyzed
using commercially available software (Ingenuity Sys-
tems, Redwood City, CA, USA). Ingenuity pathway ana-
lysis was performed on mRNA genes expressed in the
endometrium, comparing normal and elevated P groups;
this was to predict mRNA target genes of differentially
Table 1 The GenBank accession numbers of the primers and sequences and sizes of the amplified fragments used for
real-time PCR analysis
Gene GenBank accession no. Sequence (5’-3’) Length Amplicon size (bp)
miR-451 hsa-miR-451 RT:GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACaactca
AS: GCGAAACCGTTACCATTACTGA
Spp1 NM_000582 R:TGGGGTCTACAACCAGCATA
F:ACATCTTTGCGTTTTCTACCG
20
20
103
Ang NM_001145 R:CTGTGGTTTGGCATCATAGTG
F:CATGTACGTTGCTATCCAGGC
21
21
264
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mine the statistical significance.
Results
The relationship between miRNA and the target mRNA
in endometrial receptivity was determined to assist in
the determination of the molecular pathways that affect
receptivity between higher and normal P levels.
miRNA microarray screening
A total of 4 down-regulated miRNAs demonstrated sta-
tistically significant differential expression between the
control, normal P, and elevated P groups (fold change
< 0.2); this implies that four miRNAs exhibited a relative
decreased expression (hsa-miR-451, hsa-miR-424, hsa-
miR-125b, and hsa-miR-30b; Figure 1 and Table 2).
mRNA microarray screening
Total endometrial RNA from five samples per group was
extracted by dilation and curettage. These RNA prepara-
tions were then used to probe the human gene
microarray comprised of 21,522 genes. Only those genes
with a q value <5% in the one class method from SAM
analysis and a ratio of at least 2-fold difference among
the groups, were considered. A total of 22 genes dis-
played significant (P < 0.05) decreases in expression from
endometrial samples taken during the implantation win-
dow between the groups. Among the 22 mRNA genes, 13
up-regulated and 9 down-regulated were detected in the
elevated P group (Figure 2 and Table 3). In an effort to
further explore the biologic relationship between reduced
Figure 1 Four down-regulated miRNAs possessing significant differential expression between normal progesterone and elevated
progesterone groups (fold change <0.2).
Table 2 Relative expression of miRNAs decreased in
endometrial samples taken during the implantation
window between the groups, as shown by miRNA
microarray analysis
Fold change q value (%) HUGO name
0.123 0 hsa-miR-451
0.135 0 hsa-miR-424
0.185 0 hsa-miR-125b
0.186 0 hsa-miR-30b
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Page 4 of 9Figure 2 Thirteen up-regulated and 9 down-regulated genes between normal and elevated progesterone groups (fold change >2 up-
regulated and <0.5 down-regulated).
Table 3 Relative expression of mRNAs decreased in endometrial samples taken during the implantation window
between normal and elevated progesterone groups, as shown by mRNA microarray analysis
Fold
change
q value (%) Description HUGO
name
GenBank accession no.
2.7119 13.1050 Serine-protein kinase ATM Atm NM_000051,NM_138292
2.6390 5.7126 Proteinase activated receptor 1 precursor (PAR-1) F2r NM_001992
2.5389 9.0200 Osteopontin precursor (Bone sialoprotein 1) Spp1 NM_000582
2.5156 5.7126 SA hypertension-associated homolog isoform 1 Sah NM_202000,NM_005622
2.4192 13.1050 Lysozyme C precursor Lyz NM_000239
2.3716 9.0200 Kinetochore associated 2 Kntc2 NM_006101
2.1913 5.7126 Liver carboxylesterase 1 precursor Ces3 NM_001266
2.1760 9.0200 N-acetylgalactosamine kinase Galk2 NM_001001556,NM_002044
2.1591 13.1050 Alcohol dehydrogenase; Fe-containing alcohol dehydrogenase 1 Adhfe1 NM_144650
2.1208 13.1050 Heterogeneous nuclear ribonucleoproteins A2/B1 Hnrpa2b1 NM_002137,NM_031243
2.0778 5.7126 Influenza virus NS1A binding protein; NS1-binding protein Ivns1abp NM_016389,NM_006469
2.0611 13.1050 Lactamase, beta 2 Lactb2 NM_016027
2.0439 9.0200 Ubiquitin carboxyl-terminal hydrolase 16 Usp16 NM_006447,NM_001001992
0.4958 35.2491 Histone deacetylase 5 (HD5) Hdac5 NM_005474,NM_139205
0.4796 32.6148 1-acyl-sn-glycerol-3-phosphate acyltransferase beta Agpat2 NM_006412
0.4305 5.1933 Angiogenin precursor Ang NM_001145
0.4253 32.6148 LAG1 longevity assurance homolog 4 Lass4 NM_024552
0.4141 35.2491 Fibrinogen beta chain precursor Fgb NM_005141
0.4102 32.6148 Similar to lymphocyte antigen 6 Complex, locus G5B; G5b protein; open
reading frame 31
Np_660282 NM_145239
0.3214 32.6148 Left-right determination factor B precursor Leftb NM_020997
0.2476 32.6148 WNT1 inducible signaling pathway protein 2 precursor (WISP-2),
(Connective tissue growth factor-like protein) (CTGF-L), (Connective tissue
growth factor-related protein 58)
Wisp2 NM_003881
0.1734 35.2491 Tyrosinase precursor Tyr NM_000372
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Database for predicting mRNA targets of the miR-451
(the most differentially expressed, fold change = 0.12)
was conducted. The Sanger Database-predicted mRNA
gene targets of miR-451 were then cross-referenced
against the 22 mRNA genes; indeed, it was shown that
miR-451 gene targets were differentially expressed
between normal and elevated P endometrium genes from
the Affymetrix microarray expression analysis. Four of 22
(18%) differentially expressed genes, Tyr (tyrosinase pre-
cursor), Usp16 (ubiquitin carboxyl-terminal hydrolase
16), Galk2 (N-acetylgalactosamine kinase), and Spp1
(osteopontin precursor) were also predicted mRNA tar-
gets of miR-451.
Real-time PCR
In an effort to validate the array expression findings, one
of the four differentially-expressed miRNAs (hsa-miR-
451) was chosen for real-time PCR (RT-PCR) analysis
(Figure 3); three samples were taken per group. The
expressions proved to be lower in group 2 (34.3%, 47.4%,
and 39.9%; average, 40.56%) than in group 1 (44.43%,
100%, and 82.85%; average, 75.76%). Two of the 22
differentially-expressed mRNA (Spp1 and Ang) were cho-
sen for RT-PCR analysis (Figure 3). Spp1 was one of the
4 miR-451 regulated genes. We also chose 3 samples per
group for RT-PCR analysis. Spp1 expression was higher
(group 1: 12.12%, 26.65%, and 57.89%; average, 32.22%
vs. group 2: 40.21%, 42.90%, and 44.17%; average,
42.43%), while Ang expression was the lower (group 1:
80.68%, 78.34%, and 30.05%; average, 63.03% vs. group 2,
37.36%, 87.60%, and 55.38%; average, 60.11%). These
results totally supported the accuracy of the mRNA
microarray analysis.
Protein verification
In order to explore the biological significance of the Spp1
and Ang genes, their expression in normal and elevated P
endometrium were analyzed by imunohistochemistry
methods. The results demonstrate that osteopontin and
vascular endothelial growth factor (VEGF) proteins were
found in both normal and elevated P endometrial tissues,
both stromal and glandular cells. The osteopontin was
staining more intense and VEGF less intense in women
with high versus normal serum P group, as calculated by
the H-score (Figure 4 and Table 4).
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Figure 3 Validation of hsa-miR-451, Spp1, and Ang gene expression between the groups. Group 1: normal progesterone group; group 2:
elevated progesterone group. 3 endometrium samples per group were involved. 1: hsa-miR-451 gene expression; 2a: Spp1 gene expression; 2b:
Ang gene expression.
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Successful implantation of embryos is an important
physiologic event in the establishment of pregnancy
[17]. High serum P concentrations could have an
adverse effect on endometrial conditions, a pattern
observed through our clinical research [4]. However,
what factors affect endometrial receptivity of high P
patients? Global gene expression analysis has been
used to search the etiologic factors of many diseases
[18]. In recent years, many studies have been con-
ducted to explore the cause of endometrial receptivity
reduction [19]. Our study used a gene array to investi-
gate the expression of differential genes in the endo-
metrium in patients with elevated P; this was chosen
because of the extremely poor outcome in IVF-ET
treatment observed in these individuals. Some of the
22 genes identified proved to be involved in invasive
growth and the cystoskeleton; among them, a number
have been previously reported to affect endometrial
receptivity directly or indirectly, including oesteopontin
[20] and angiogenin (which regulates VEGF expres-
sion) [21].
A
B
C
12
Figure 4 Osteopontin and vascular endothelial growth factor (VEGF) proteins expressed in normal, and elevated progesterone
endometrium by immunohistochemistry methods. Group 1: normal progesterone group; group 2: elevated progesterone group. A:
Osteopontin; B: vascular endothelial growth factor; C: negative control.
Table 4 Different expression of OPN and VEGF in
endometrial samples taken during the implantation
window between normal and elevated progesterone
groups, as shown by imunohistochemistry analysis
Group 1 Group 2 tP
Samples 7 12
OPN 313 ± 29 362 ± 19 -4.036 0.003
VEGF 343 ± 34 304 ± 28 2.683 0.016
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series of miRNA which may contribute to reductions in
endometrial receptivity. By executing a parallel analysis
of mRNA levels in a subset of these samples, we have
identified a panel of mRNAs that may influence endome-
trial receptivity. A proportion of these mRNA genes have
been previously reported as predicted targets of the
miRNA [22]. Using the Sanger miRNA database, several
of the differentially-expressed genes have been identified
as target genes for miRNA in this study, which may play
an important role in reducing endometrial receptivity.
Furthermore, we have identified 4 miRNAs and 22
mRNA genes that were differentially-expressed between
normal and elevated P endometrium. Using the Sanger
database, 4 of the 22 mRNA genes were identified as pre-
dicted targets of the miRNA-451; several of these mRNA
genes are associated with endometrial receptivity.
The relationship between miRNA gene expression and
the mRNA targets is very complicated. It is believed
that miRNA influences cell function via post-transcrip-
tional modulation [23]; thus, the effect of miRNA is lar-
gely directed toward post-transcriptional activity. The
post-transcriptional down-stream effects of miRNA on
translation may operate on a feedback-loop, with conse-
quences impacting mRNA transcription of the miRNA
predicted targets. Moreover, the effect of miRNA on
messenger RNA degradation may also result in changes
in mRNA levels that may be detected through an array
expression analysis.
Osteopontin is an important factor because of its invol-
vement in the implantation process. This glycoprotein is a
ligand for a v b3 integrin; osteopontin mediates cellular
adhesion and migration during embryo implantation and
is regulated by P. Its maximal expression in endometrial
epithelial cells has been observed during the window of
implantation [24]. VEGF and its receptor had intense
expression in the endometrial epithelial cells of the
implantation widow and also showed stromal immunor-
eactivities by the time that secondary villi differentiate into
tertiary villi [25]. When there were some abnormal expres-
sions of cytokines, such as OPN and VEGF, the endome-
trial receptivity decreased, which led to poor pregnancy
rate in IVF patients. A better pregnant outcome in frozen
ET cycles may be achieved when the patient has an ele-
vated P following the administration of hCG.
Conclusions
We performed a gene pathway analysis on miRNA and
mRNAs in order to report the effects of this differen-
tial expression between normal and elevated P. This
pathway analysis identified osteopontin and angiogenin
to play an important role in endometrial receptivity of
elevated P. All this data may provide a reason to
explain the reduced pregnancy rate in patients with
elevated P, thus creating new markers for improved
treatment for patients undergoing IVF-ET with ele-
vated P levels.
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